List of Biologics Companies in Delaware - 11

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

Providing value-based care to our community, ONE PERSON AT A TIME. ChristianaCare, headquartered in Wilmington, Delaware, is one of the country's largest health care providers, ranking 22nd in the nation for hospital admissions. ChristianaCare is a major teaching hospital with two campuses and more than 250 Medical-Dental residents and fellows. ChristianaCare is recognized as a regional center for excellence in cardiology, cancer and women's health services. The system is home to Delaware's only Level I trauma center for adults and children, the only center of its kind between Philadelphia and Baltimore. ChristianaCare also features a Level III neonatal intensive care unit, the only delivering hospital in the state to offer this level of care for newborns. A not-for-profit, non-sectarian health system, ChristianaCare includes two hospitals with more than 1,100 patient beds, a home health care service, preventive medicine, rehabilitation services, a network of primary care physicians and an extensive range of outpatient services. With more than 11,600 employees, ChristianaCare is the largest private employer in Delaware and among the top 10 in the Philadelphia region. Statistics at a Glance: Among hospitals in the United States, ChristianaCare's ranking by volume is: 22nd in admissions. 32nd in births. 24th in emergency visits. 32nd in total surgeries. Among hospitals on the East Coast, ChristianaCare ranks: 12th in admissions. 16th in births. 15th in emergency visits. 19th in total surgeries. (Source: American Hospital Association Annual Survey Database of 6,200 U.S. Hospitals, 2017, © Health Forum, LLC) Awards: Christiana Care is continually recognized for excellence on a regional and national level. These are some of our recent awards. Click to see more at http://www.christianacare.org/Awards

Gene Editing Institute V1 is a biotechnology company that advances the power of CRISPR gene editing technology to improve human life through groundbreaking research and development.

Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity. Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia. We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list. For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.

NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes and animals. Our technology targets two special cellular components known as organelles that harbor their own DNA. Those organelles are called mitochondria and chloroplasts. Both organelles are important to create energy for cells to grow. They are also critical for producing various biochemical molecules key to specific pathways and functions. Our genome technology has broad application areas. They range from industrial biotechnology to animal and human healthcare as well as to agriculture. Our mission is to harness the potentials of organelles to make our society a better place to live.

Precisio Biotix Therapeutics is US incorporated industry leader in precision antibacterial biological solutions; specifically the identification and development of lysin and phage products to combat bacterial infections or difficult to treat bacterial issues. Products created with lysins and phages are novel precision solutions to address the declining effectiveness of existing treatments. LysiThru™,the Company's industry-leading, high-throughput lysin screening system, is capable of rapidly creating new gram-positive and gram-negative lysins for almost every pathogen. The Company has a robust pipeline of commercial products with both Rx and consumer commercial opportunities. - Multiple gram positive and gram negative systemic lysins, with a focus on skin and lung infections. - Bactelide™, a sustained release biodegradable phage product to prevent and treat topical infections - Several topical lysins with consumer-oriented uses

RevOpsis Therapeutics is a next-generation biopharmaceutical company that is trailblazing a new era in multispecific antibody discovery and development to unlock transformative treatments for complex disease. Our process is simple. Our proprietary Rev-Mod Platform uses a modular plug-and-play system to streamline drug discovery and development. The Rev-Mod Platform features a library of ~30 billion fully human and fully compatible antibody components that are ready to be assembled into functional Multi-Mod biologics. Using this platform, we can select and integrate multiple antibody components into a single, multispecific therapeutic molecule that binds targets implicated in known, clinically validated disease pathways. Our lead asset from this platform, RO-104, is a first-in-class trispecific biologic. RO-104 targets 3 clinically validated pathways that are implicated in retinal vascular diseases, such as neovascular age-related macular degeneration (nAMD). Whereas current anti-VEGF therapies used to treat nAMD predominantly target only the VEGF-A pathway, RO-104 builds on a body of literature that suggests that combining the targeting of VEGF-A, VEGF-C, and Ang-2 can improve patients’ therapeutic gains and extend treatment durability. RO-104 has the potential to offer these benefits with a single therapeutic molecule, as preclinical studies indicate high affinity to all 3 targets, efficacy in a choroidal neovascularization model, and ideal drug-like properties.

At Sensible Biotechnologies, we are turning living cells into cost-efficient factories for manufacturing high-quality mRNA to unlock the full potential of mRNA therapeutics and vaccines. 

Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world. Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.

At Virion Therapeutics, We Believe a Future Free of Cancer and Chronic Infectious Diseases Is Within Reach​ Driven by science, our mission is to revolutionize the immunotherapy treatment landscape, focusing on the development of novel, adaptable, and accessible CD8+ T cell-based technologies.​ Our transformative platform is first in its class, offering a unique methodology that combines innovative and established approaches to elicit a superior CD8+ T cell response. Novel genetically encoded checkpoint modifiers are delivered alongside optimized target-specific antigens via an immunogenic and adaptable viral vector platform that promotes potent, prolonged, and broad CD8+ T cell responses. With potential applications across a range of cancers and chronic infectious diseases, our proprietary technology provides us with a robust pipeline. Our lead product, VRON-0200, is under investigation as a potential functional cure for the treatment of chronic hepatitis B virus (HBV) – a first-in-human clinical study is planned to initiate in late 2022. Founded in 2018 to advance technology licensed from The Wistar Institute, we have assembled a world-class management team and an industry-leading global Board of Directors, with proven experience in the biotechnology sector, as well as extensive preclinical and clinical expertise in antiviral, vaccine, oncology, and immuno-oncology.​

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 12,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $4.5 billion.